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S U M M A R Y
Objectives: To estimate the impact of immune reconstitution inﬂammatory syndrome (IRIS) on
morbidity and mortality in patients starting highly-active antiretroviral therapy (HAART).
Methods: A retrospective cohort study of HIV-positive patients starting HAART was conducted at a
tertiary care referral center in Mexico City. We estimated the incidence of IRIS, hospitalizations and
death rates during the ﬁrst 2 years of HAART. The relative risk of death (RR) and hospitalization for
patients with IRIS were adjusted for relevant covariates using regression methods.
Results: During the 2-year follow-up period, 27% of patients developed IRIS (14 IRIS cases per 100
person-years). The relative risk of death among patients who developed IRIS was 3 times higher (95%
conﬁdence interval (CI) 1.19–7.65, p = 0.03). After adjusting for previous opportunistic infections we still
observed a higher death rate among patients with IRIS (RR 2.3, 95% CI 0.9–5.9, p = 0.09). An effect
modiﬁcation of IRIS over mortality was observed by previous opportunistic infection.
Conclusions: IRIS-associated mortality is strongly confounded by previous opportunistic infection.
Patients with AIDS who eventually developed IRIS had the highest risk of death at the 2-year follow-up.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The use of highly active antiretroviral therapy (HAART) leads to
quantitative and qualitative changes in the immune response that
have dramatically improved the survival and quality of life of
people livingwith HIV.1–4 However, HAART initiation is sometimes
associated with a paradoxical reaction characterized by a
generalized inﬂammatory response or a localized inﬂammation
of tissues previously infected with opportunistic pathogens.5,6 The
manifestations of this inﬂammatory response have been grouped
together under the term immune reconstitution inﬂammatory
syndrome (IRIS) or immune reconstitution disease (IRD).
Previous observational studies suggest that IRIS has a major
effect on morbidity in HIV-infected patients starting antiretroviral
treatment, but its impact on mortality is yet to be established.7–10
Moreover, it has been suggested that IRIS has a role in the early
mortality of patients starting antiretroviral (ARV) therapy at§ This study was presented in part at the 5th International AIDS Society
Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South
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doi:10.1016/j.ijid.2011.02.007advanced stages of the disease,11 but to date few studies have
addressed this issue.8,9,12 We conducted a retrospective study in a
cohort of HIV-infected patients receiving HAART in an HIV/AIDS
clinic in Mexico City. Herein we describe the incidence of IRIS and
mortality rate during the ﬁrst 2 years of ARV therapy in our clinic,
and comparemortality rates in patients with IRIS andwithout IRIS.
We also compare the hospitalization rate between groups to
estimate the impact of IRIS on morbidity.
2. Methods
2.1. Study design and population
The source population for this retrospective cohort analysis was
all HIV-infected adults receiving medical care at the HIV/AIDS
clinic of the Instituto Nacional de Ciencias Me´dicas y Nutricio´n
Salvador Zubira´n (INCMNSZ). The INCMNSZ is a tertiary care
referral center located inMexico City that providesmedical care for
people from different regions of the country. Patients who began
ARV therapy between October 2001 and November 2007 were
included in this study if they had attended at least one documented
medical visit to the HIV clinic after starting HAART. Information
through December 31, 2008 was included in the analysis. Patients
were considered as lost to follow-up if they had a period of a year orses. Published by Elsevier Ltd. All rights reserved.
I. Hoyo-Ulloa et al. / International Journal of Infectious Diseases 15 (2011) e408–e414 e409longer without visits by that day, or did not complete a 2-year
follow-up period. Patients starting treatment during this period at
other hospitals who were afterwards referred to continue their
care at our clinicwere excluded from the analysis. The institutional
review board of the INCMNSZ waived the informed consent
process for the use of clinical data for retrospective analysis and
publication as part of the CCASAnet collaboration (Caribbean,
Central and South America Network for HIV Research).13
2.2. Data collection
The HIV/AIDS clinic has been prospectively recording demo-
graphic, clinical, and laboratory information for each patient since
2000, and maintains an electronic database with this information
that is updatedonadaily basis. The database is sporadically updated
with an active search for those patients whowere lost to follow-up;
the last update occurred in March 2007. All patients starting ARV
treatment were identiﬁed using the electronic database. Demo-
graphic information, medical history prior to HAART initiation, and
laboratory baseline information was retrieved from the database.
Information on clinical symptoms and conditions after HAART
initiation was retrieved from the medical ﬁles.
2.3. Assessment of IRIS
Using a standardized format, information from patient medical
records was collected to evaluate the appearance of symptoms or
conditions previously identiﬁed as related to IRIS (fever, lymph
node enlargement, oral lesions, worsening clinical manifestations
of previously diagnosed opportunistic infections (OIs), neurologi-
cal deﬁcit, pneumonia, tuberculosis, herpes zoster, skin changes,
and visual disturbances). All ﬁles of patients with any of these
symptoms were independently reviewed by two infectious
diseases specialists (BCR and JSM) with experience treating HIV-
infected patients, to determine whether the clinical information
gathered in the ﬁles were IRIS events. An IRIS event was deﬁned a
priori using the AIDS Clinical Trials Group (ACTG) immune
reconstitution inﬂammatory syndrome generic criteria (revised
May 24, 2005). All IRIS events were classiﬁed as either ‘probable’ or
‘conﬁrmed’. Patients whose condition did not meet the ACTG
criteria were registered as having an ‘event not related to IRIS’.
Additionally, an IRIS episodewas considered either ‘paradoxical’ or
‘unmasking’, extrapolating the classiﬁcation created by the
International Network for the Study of HIV-associated IRIS for
tuberculosis to all other IRIS-related clinical entities.14 In brief, an
unmasking IRIS event was deﬁned as all new OIs diagnosed after
starting HAART with speciﬁc atypical features or excessive
inﬂammatory manifestations, while a paradoxical IRIS event was
said to be a worsening or recurrent clinical manifestation of a
previously diagnosed and successfully treated OI within a 6-month
period after starting HAART. We also classiﬁed events as severe or
not severe, deﬁned a priori as follows.We considered severe IRIS to
have occurred when this event led to the patient’s hospitalization,
to the use of an invasive life support measure, or the requirement
of a major invasive diagnostic or therapeutic intervention (e.g.,
bronchoscopy, abdominal or thoracic exploratory surgery, cerebral
biopsy, blood transfusion, or any surgical procedure). Date of start
of an IRIS event was considered as the ﬁrst date when new
symptoms of a condition that was ﬁnally diagnosed and classiﬁed
as an IRIS event or worsening of a pre-existing condition were
registered in the medical ﬁle.
2.4. Outcome ascertainment
Hospitalizations and deaths were ascertained from death
certiﬁcates, medical charts, and the HIV/AIDS clinic database. Inthe IRIS group we collected hospitalization data exclusively on
those hospital admissions related to the IRIS event, while for the
non-IRIS group, all hospitalizations were included in the analysis.
2.5. Assessment of other variables
The analysis included other variables to control for potential
confounding effects. These variables were modeled as time-ﬁxed,
and the value taken was that at the time of HAART initiation.
We considered sex, HIV viral load >75 000 copies/ml (this cut-
off value was used because our study included patients from 2001,
and at this time the upper limit of viral load detection was 75 000
copies/ml at our center), the presence of OIs before HAART
initiation, and type of HAART (protease inhibitors vs. non-
nucleoside reverse transcriptase inhibitors (NNRTIs)) as binary
variables. Age, weight, and CD4+ T cell counts were classiﬁed as
continuous variables. Finally, the type of OI previous to HAART
initiation, behavioral risk group, and type of HAART regimen were
considered categorical variables with discrete values.
2.6. Statistical analysis
The primary outcome measure was death during the ﬁrst 24
months after HAART initiation. The secondary outcome was the
ﬁrst episode of hospitalization after HAART initiation within the
ﬁrst 24 months of HAART. Patients were considered exposed after
having had an IRIS event and thereafter, regardless of the duration
of the IRIS event. Consequently, subjects contributed to person-
time at risk exposed to IRIS only after they had the IRIS event.
Patients were censored at death, treatment interruption, last
documented visit to the clinic or at 2 years after HAART initiation.
Characteristics of patients at the date of HAART initiation are
described using proportions and the median and interquartile
range (IQR) as measures of central tendency and dispersion.
Fisher’s exact test andWilcoxon non-parametric tests were used as
appropriate to compare differences in proportions and distribution
of characteristics between patients with and without IRIS. Patient
follow-up (person-time at risk) began at the date of HAART
initiation. The incidence rate of IRIS was calculated by dividing the
number of IRIS events by person-time at risk, expressed in number
of cases per 100 person-years.
During the exploratory data analysis, we used a Cox propor-
tional hazards model to search for risk factors for IRIS that could
also predict death, in order to identify their roles as potential
confounders in the ﬁnal analysis. In order to estimate the relative
risk of death, rate ratios (RR) and two-sided 95% conﬁdence
intervals (CI) were derived from hazard ratios obtained from the
Cox proportional hazard regression model, adjusting for CD4+ T
cell counts, weight, and age at baseline. We ﬁrst ﬁtted a model
containing the variables sex, age, weight, baseline CD4+ T cell
counts and the presence of OIs diagnosed before starting HAART,
HIV viral load and type of HAART regimen, and then removed
variables that did not independently predict death (except for
CD4+ T cell count which was included in the ﬁnal model, as it has
been consistently observed to be the main predictor of survival
among HIV-infected patients) based on an a priori deﬁneda of 0.2.
To evaluate the differentiated effect of IRIS on mortality by
different baseline characteristics, we used an interaction term for
IRIS with baseline characteristics of interest. The validity of the
proportional hazards assumption was assessed graphically with a
complementary log–log plot and using the Grambsch–Therneau
method.15 We used Kaplan–Meier estimates to construct survival
curves and compared the cumulative hazards function using the
log-rank test.
To estimate hospitalization rates, we only considered the ﬁrst
hospitalization after HAART initiation. Patients were censored at
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the clinic or at 2 years after HAART initiation. Hospitalization RR
and two-sided 95% CI were estimated using a Poisson regression
model to adjust for baseline CD4+ T cell count, weight, and the
occurrence of OIs before HAART initiation. The procedures for
ﬁtting this regression model were similar to those described to
estimate the mortality rate ratio.
Missing data onweight (2.8%), CD4+ T cell count (1.3%), and HIV
viral load (8.2%) at baseline was imputed using simple imputations
based on multivariate regression models. Statistical analysis was
performed using STATA version 10.16
3. Results
3.1. Cohort patient characteristics
Between October 2001 and November 2007, 413 patients
initiated HAART. Of these, 23 (6%) cases were excluded from the
analysis because they started treatment at other centers and were
referred to our clinic to continue their follow-up. The 390 patients
included in the analysis contributed 756 person-years of follow-
up, with a median of 730 days of follow-up (interquartile range
(IQR) 591–730 days). Demographic and clinical baseline char-
acteristics of the cohort are presented in Table 1. On December 31,
2008 all patients, except those who had died (5%), continued on
follow-up or had completed 2 years of follow-up.
Patients were mostly young adults (median age 35 years), most
were male (88%), and all had started treatment either with an
NNRTI-based regimen (efavirenz, 67%) or a protease inhibitor
(33%) regimen. One hundred and twenty-eight patients (33%) had
had an OI diagnosed before starting HAART, and 27 (21%) of them
had had at least two diagnosed OIs before starting therapy. The
most common OIs diagnosed before HAART were Pneumocystis
jirovecii pneumonia (PCP; 32 events), tuberculosis (21 events), and
Kaposi’s sarcoma (14 events). Only three patients had cryptococcal
meningitis before HAART and none of them developed IRIS. Having
a particular OI before HAART did not increase the risk of death.
3.2. Immune reconstitution inﬂammatory syndrome
During the 2-year follow-up period, 107 (27%) patients
developed IRIS, corresponding to an incidence rate of 14 IRIS
cases per 100 person-years of follow-up. The median onset of IRIS
was 69 days (IQR 20–193 days), and the median duration of the
episodes was 17 days (IQR 8–39 days). Of the 107 cases, 16 (15%)
were classiﬁed as probable and 91 (85%) as conﬁrmed.
Themicroorganismmost frequently associatedwith IRIS events
was varicella zoster, accounting for 32% of all IRIS cases (see TableTable 1
Baseline characteristics of HIV-infected adults receiving medical care at the INCMNSZ
Baseline characteristics Total (N=390) (100%)
Male 342 (88%)
Age, median (IQR) 35 (29–42)
Weight in kg, median (IQR) 62 (54–70)
CD4+ cell/ml, median (IQR) 87 (32–184)
HIV-1 viral load, copies/ml
75 000 293 (75%)
<75 000 97 (25%)
HAART regimen
NNRTI 263 (67%)
Protease inhibitor 127 (33%)




Results are n (%), unless otherwise speciﬁed. INCMNSZ, Instituto Nacional de Ciencias
syndrome; IQR, interquartile range; HAART, highly-active antiretroviral therapy; NNRT2), all of them in patients with no prior herpes zoster episodes and
with no severe episodes. The median onset of varicella zoster-
related IRIS after HAART initiation was 143 days (IQR 56–332
days). Other frequent presentations of IRIS were Mycobacterium
tuberculosis (12 events, 11% of all IRIS cases),Mycobacterium avium
complex (MAC; 10 events, 9%), PCP (six events, 6%), Cryptococcus
neoformans (ﬁve events, 5%), Kaposi’s sarcoma (four events), and
cytomegalovirus (four events) associated IRIS. Most cases of
tuberculosis-associated IRIS8 presented as tubercular lymphade-
nitis, in two patients it presented as pulmonary tuberculosis (one
unmasking and one paradoxical), and in two others as intestinal
tuberculosis (both paradoxical). Tuberculosis-associated IRIS
developed in eight of the 21 (38%) patients previously diagnosed
with tuberculosis (paradoxical tuberculosis) and accounted for
most of the paradoxical IRIS events (see Table 2). Paradoxical
tuberculosis-associated IRIS tended to present earlier after HAART
initiation (median 15.5 days, IQR 12–26.5 days) than unmasked
tuberculosis IRIS (median 58.5 days, IQR 26–76 days). The median
onset of presentation in MAC-associated IRIS was 29 days after
HAART initiation (IQR 8–58 days), and most cases presented as
lymphadenitis (nine cases). Four cases of C. neoformans IRIS
presented as cryptococcal meningitis and one as lymphadenitis.
Unmasking cases were more frequent (n = 87, 81%) than
paradoxical cases (n = 20, 19%). Overall, patients with unmasking
and paradoxical cases were similar with regards to age, weight,
CD4+ T cell count, proportion of males, and patients with a high
viral load (>75 000 copies). In total, 17 patients (16%) presented
with severe forms of IRIS; those with the paradoxical form were
more likely to develop severe events as compared to those with
unmasking events (35% vs. 11%, p = 0.017) (see Table 2).
Patients with IRIS had on average lower weight and CD4+ T cell
count at baseline than patients without IRIS, and were more likely
to have had anOI before HAART initiation (Table 1). These variables
remained independently associated with IRIS when adjusting for
potential confounders (see Table 3).
The most common OIs diagnosed before HAART among the 107
patients who developed IRIS were tuberculosis (12 events; seven
disseminated and ﬁve pulmonary), PCP (10 events), disseminated
histoplamosis (seven events), and Kaposi’s sarcoma (six events).
Patients with tuberculosis, but not those with any other OIs before
HAART initiation, had an increased risk for developing IRIS (RR 3.5,
95% CI 1.9–6.4) after adjusting for baseline CD4+ T cell count and
weight (see Table 3).
3.3. Mortality associated with IRIS
During the 2 years of follow-up, the cumulative all-cause
mortality in the cohort was 4.9%, corresponding to a mortalityIRIS (n=107) (27%) No IRIS (n=283) (73%) p-Value
96 (90%) 246 (87%) 0.5
34 (28–41) 35 (30–42) 0.46
58 (48–67) 63 (55–71) 0.0005
48 (20–110) 113 (40–205) <0.0001
86 (80%) 207 (73%) 0.15
21 (20%) 76 (27%)
73 (68%) 190 (67%) 0.9
34 (32%) 93 (33%)
55 (51%) 73 (26%) <0.001
20 (19%) NA NA
87 (81%)
Me´dicas y Nutricio´n Salvador Zubira´n; IRIS, immune reconstitution inﬂammatory
I, non-nucleoside reverse transcriptase inhibitor; NA, not applicable.
Table 2
Description of 107 patients who presented IRIS, according to clinical presentation
Characteristic Unmasking n=87 (81%) Paradoxical n=20 (19%) p-Value
Male 78 (90%) 18 (90%) 1.0
Age, median (IQR) 34 (28–42) 34 (28–37) 0.6
Weight, median (IQR) 60 (48–67) 55 (46–64) 0.25
CD4+ T cells, median (IQR) 52 (22–117) 35 (12–73) 0.12
CD4+ <50 cells/ml 41 (47%) 14 (70%) 0.085
CD4+ <200 cells/ml 77 (89%) 19 (95%) 0.68
HIV RNA viral load >75 000 copies/ml 70 (80%) 17 (85%) 0.46
NNRTI 61 (70%) 12 (60%) 0.27
Previous opportunistic infection 35 (40%) NAa (100%) NA
Days of onset after HAART initiation, median (IQR) 80 (28–199) 27 (13–114) 0.02
Type of IRIS event
Varicella zoster (34 events) 34 (39%) 0 <0.01
Mycobacterium tuberculosis (12 events) 4 (5%) 8 (40%) <0.01
Mycobacterium avium complex (10 events) 8 (9%) 2 (10%) 0.57
Pneumocystis jirovecii pneumonia (6 events) 4 (5%) 2 (10%) 0.13
Cryptococcus neoformans (5 events) 2 (2%) 3 (15%) 0.04
All other (40 events) – – –
Duration of the event in days, median (IQR) 14 (7–39) 25 (18–38) 0.06
Survival time after IRIS event, median (IQR) 42 (20–288) 33b –
Severe presentation 10 (11%) 7 (35%) 0.017
Deaths 7 (8%) 1 (5%) 0.6
Results are n (%), unless otherwise speciﬁed. IRIS, immune reconstitution inﬂammatory syndrome; IQR, interquartile range; NNRTI, non-nucleoside reverse
transcriptase inhibitor; HAART, highly-active antiretroviral therapy; NA, not applicable.
a By deﬁnition, all paradoxical cases had a previous opportunistic infection.
b Only one patient with paradoxical IRIS died.
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time after an IRIS event was 39 days (IQR 27–166 days). The
mortality rate among patients who did not develop IRIS was 1.8
deaths per 100 person-years in comparison to 4.9 deaths per 100
person-years among patients who had an IRIS event. The crude
mortality ratio was 3.02 (95% CI 1.19–7.65, p = 0.03) when
comparing patients with IRIS to patients without IRIS. After
adjusting for age, CD4+ T cell count, and weight, the mortality
ratio was 2.86 (95% CI 1.08–7.58, p = 0.03). When we introduced
the presence of OIs before HAART initiation into the model, the
mortality ratio decreased to 2.28 (95% CI 0.87–5.99, p = 0.09) (see
Table 4).
We observed that the diagnosis of an OI before starting HAART
modiﬁes the effect that IRIS has on the 2-yearmortality (see Table
5). Figure 1 shows the differences in the 2-year cumulative risk of
death according to the presence of an OI previous to HAART and
subsequent development of IRIS. The log-rank test (p = 0.004)
indicates that the risk of death was signiﬁcantly different across
strata, with patients with OIs diagnosed before starting HAART
who subsequently developed IRIS being at the highest risk of
death in the 2 years of follow-up (RR 8.1, 95% CI 2.4–27.5,
p = 0.001).Table 3
Baseline characteristics associated to the risk of IRIS





Male vs. female 1.3 (0.7–2.4) –
Agea 0.9 (0.8–1.1) –
Weightb 0.7 (0.6–0.9) 0.8 (0.7–0.9)
CD4+ T cells (<200 vs. >200 cells/ml) 2.8 (1.5–5.2) 2 (1.1–3.8)
HIV RNA viral load




2.8 (1.9–4) 2.2 (1.5–3.3)
Tuberculosis (yes vs. no) 3.8 (2.1–7) 3.5 (1.9–6.4)
IRIS, immune reconstitution inﬂammatory syndrome; CI, conﬁdence interval.
a Increased risk per every 10 years increase in age.
b Increased risk per every 10kg increase in weight.3.4. Hospitalization associated with IRIS
During the 2 years of follow-up, 59 patients (15%) in the cohort
were hospitalized at least once, corresponding to an incidence rate
of 2.4 hospitalizations per 100 person-years taking into account
only the ﬁrst hospitalization. A greater proportion of patients with
IRIS than without IRIS were hospitalized (32% vs. 9%, p < 0.001),
and patients with IRIS spent on average 6.1 days hospitalized in
comparison with 1.4 days among patients without IRIS. The
hospitalization rate among patients who did not develop IRIS was
1.2 per 100 person-years in comparison with 6.1 per 100 person-
years among patients who developed IRIS. The unadjusted
hospitalization rate ratio was 3.6 (95% CI 2.2–6.03, p < 0.001)
when comparing patients with IRIS to patients without IRIS. After
adjusting for age, baseline CD4+ T cell count, presence of OI prior to
HAART initiation, and weight, the hospitalization ratio was 3.2
(95% CI 1.9–5.6, p < 0.001) (see Table 4).
4. Discussion
In this retrospective cohort study of HIV-infected patients
starting ARV therapy in Mexico, the crude mortality ratio of
patients with IRIS when compared with patients without was 3.02
(p = 0.03), but after adjusting for the relevant confounders it
decreased to 2.3 (p = 0.09). We also observed that the effect of IRIS
on mortality differed depending on whether the patient had a
previously diagnosed OI or not.
The cumulative incidence of IRIS for this period was 27%, which
is consistent with previously published cohort studies in which
IRIS has been shown to present during the ﬁrst weeks after
beginning ARV therapy in about 12–45% of patients who start
treatment at very low CD4+ cell counts.5,8,17,18 The variability in
the occurrence of IRIS may be explained by the local prevalence of
the involved pathogens, the level of immune suppression when
starting HAART in different settings, and the pathogenicity of each
microbe,7,17–20 but also by the case-deﬁnition used, as will be
discussed further.
The presence of an OI before starting HAART, a low weight or
bodymass index, and a low CD4+ T cell count have previously been
identiﬁed as risk factors for IRIS,21–23 and these same factors have
Table 4
Mortality and hospitalization rates for HIV-infected patients starting HAART according to IRIS
Total (N=390) (100%) IRIS (n=107) (27.4%) No IRIS (n=283) (72.6%) RRa (95% CI) p-Value
Deaths 19 (4.9) 8 (7.5) 11 (3.9) 2.3b (0.9–5.9) 0.09
Hospitalizations 59 (15.1) 34 (31.8) 25 (8.8) 3.2c (1.9–5.6) <0.001
HAART, highly active antiretroviral therapy; IRIS, immune reconstitution inﬂammatory syndrome; RR, relative risk; CI, conﬁdence interval.
a RR estimated by Cox regression for mortality and Poisson regression for hospitalization.
b Adjusted for age, CD4+ T cell count, presence of opportunistic infections prior to HAART initiation, and baseline weight.
c Adjusted for baseline CD4+ T cell count, presence of opportunistic infections prior to HAART initiation, and baseline weight.
Table 5
Risk ofmortality by IRIS status according to the presence of opportunistic infections




No OIs before HAART
No IRIS 1 –
IRIS 1.2 (0.1–10.8) 0.86
OIs before HAART
No IRIS 2.9 (0.9–10.1) 0.09
IRIS 8.1 (2.4–27.5) 0.001
IRIS, immune reconstitution inﬂammatory syndrome; HAART, highly active
antiretroviral therapy; CI, conﬁdence interval; OI, opportunistic infection.
a Adjusted for age, weight and CD4+ T cell counts at baseline.
b Rate ratios derived from hazard ratios (HR), estimated using a Cox Proportional
Hazards model. HR and p-values by stratum were estimated using an interaction
term between the binary variables for opportunistic infections and IRIS.
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in general.24,25 In this study, we controlled the confounding effects
of these factors using a multivariate Cox regression model. Our
results show that although patients with IRIS indeed have a higher
mortality than patients without it, the impact that IRIS may have
over mortality in patients receiving HAART is strongly confounded
by the fact that patients who develop IRIS are usually those who
start HAART at more advanced stages of the disease. The presence
of a previous OI appears to be the single most important factor
contributing to the increased mortality in patients who developed
IRIS in this cohort, as a 31% excess mortality can be attributed to























No OIs, no IRIS No OIs
Log-rank test = 0.004a
Figure 1. Kaplan–Meier survival curves comparing the adjusted survival time of patie
opportunistic infections prior to HAART initiation (IRIS, immune reconstitution inﬂamm
HAART, highly-active antiretroviral therapy). Adjusted for age, baseline CD4+ T cell coun
the four groups.regarding the effect of IRIS on mortality. Lawn et al. found a high
mortality rate among patients who developed IRIS in a cohort
receiving medical care in South Africa.12 In contrast, in a recently
published cohort analysis of 559 ARV therapy-naı¨ve patients
starting HAART in a tertiary care center in Uganda, only four out of
99 deaths were directly attributed to IRIS.9 Similar results were
observed in the single cohort study that has prospectively
evaluated the contribution of IRIS to mortality.21 The IRIS
cumulative incidence in an tertiary referral center in South Africa
was 10% at 6 months of follow-up, with a very low mortality rate
attributed to IRIS (two deaths among 44 cases of IRIS) – although
it is worth mentioning that most of their cases were deemed to
be ‘mild’.
We believe the most plausible explanations for the discrepan-
cies across data are: ﬁrst, that the studies reporting a higher
mortality among patients suffering IRIS have their analysis
restricted to speciﬁc pathogens and conditions,8,12 which may in
fact show a more severe presentation or may pose greater
difﬁculties for their treatment and medical care (e.g., tuberculosis
and cryptococcal meningitis). A recently published systematic
review of IRIS seems to conﬁrm this explanation.27 In addition, the
different methods used in the analysis of the information may also
account for disparities in the results. For instance, in the two cohort
studies carried out in South Africa, particular causes of death were
determined and the IRIS-speciﬁc mortality was assessed, in
contrast to ours, where the overall mortality rate and themortality
risk associated with IRIS were evaluated. Although it is clear that
deaths in our study cannot be attributed directly to IRIS events –
and we acknowledge this as a limitation of our study – the12 18 24
AART (months)
, IRIS OIs, no IRIS OIs, IRIS
nts who developed IRIS with patients without IRIS, according to the presence of
atory syndrome; OIs, opportunistic infections diagnosed before HAART initiation;
t, and baseline weight. aLog-rank test: tests the equality of survivor functions across
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for those who had a previous OI and subsequently developed IRIS,
deserves further consideration.
We also observed a more than three-fold increase in the risk of
hospitalization among patients who developed IRIS after adjusting
for the effect of other risk factors independently associated with
hospitalization, conﬁrming previous ﬁndings that IRIS events have
a considerable impact on morbidity in HIV-infected patients
recently started on HAART.7,18
We recognize that there are several limitations in our study.
First, the absence of a complete understanding of the IRIS decreases
the reliability of case deﬁnitions, so we can expect some degree of
misclassiﬁcation bias.10 For instance, a recent comparison of
expert opinion vs. the two published case deﬁnitions for IRIS28,29
yielded different agreement with expert opinion. Moreover, the
sensitivity of each deﬁnition varied according to the type of IRIS
event,30 despite the fact that both deﬁnitions use similar criteria.
The relatively similar incidence rate of IRIS seen in prospective
cohorts and in other studies, regardless of the case deﬁnition used,
is reassuring with regard to the potential sources of error in our
own approach. Another constraint of this study is that we
registered all-cause mortality, so we cannot claim that the
increased mortality in these patients was directly attributable to
IRIS. In addition, the general applicability of our ﬁndings may be
restricted, as our clinic operates in a tertiary-level care center in a
geographically accessible, urban setting. However, we think that
themortality directly attributed and/or associated to IRIS would be
similar, and more likely higher, in care centers with scarcer
resources that may have more limited diagnostic and therapeutic
options.
Finally, the strong association between the presence of an OI
before HAART, the subsequent development of IRIS, and an
increased risk over 2 years of mortality address an important
issue observed in patients receiving HAART in developing
countries, independently of the direct cause of death. Despite
the fact that patients receiving HAART in developing countries
have similar proportions of viral load suppression and immune
reconstitution (as measured by increase in CD4+ T cell counts)
as their counterparts in more advanced nations, it is also true
that an excess of deaths occurs within the ﬁrst few months of
therapy among patients receiving HAART in resource-poor
countries.11,31,32 The identiﬁcation of individuals at higher risk
of death after beginning ARV therapy in developing countries,
such as those who develop IRIS, may help design different health
care strategies to reduce this risk. Our study highlights the
necessity of expanding access to HIV voluntary counseling and
testing, of raising awareness about AIDS and HIV-testing to
increase early diagnosis, and of the need to start treatment
earlier,33 as starting patients on HAART at higher CD4 counts
would likely reduce the incidence of IRIS. It also provides
rational support for the evaluation of novel strategies to prevent
and treat IRIS in those HIV-infected patients at risk for this
condition.
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